Zentalis Pharmaceuticals (ZNTL) Announces CFO Change

On April 5, 2024, Melissa Epperly resigned as Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Zentalis Pharmaceuticals (NASDAQ: ZNTL), effective immediately (the “Transition Date”). The Company is conducting a search for a new Chief Financial Officer. Ms. Epperly is eligible to receive severance benefits under her Amended & Restated Employment Agreement, dated February 28, 2023, which was previously filed with the Securities and Exchange Commission on March 1, 2023 as Exhibit 10.11 to the Company’s Annual Report on Form 10-K, subject to Ms. Epperly’s entry into a release agreement with the Company.

Effective on the Transition Date, the Company’s Board of Directors (the “Board”) appointed the Company’s President, Cam Gallagher, as interim Chief Financial Officer, Treasurer and principal financial officer, and the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer. Kyle Rasbach, the Company’s Chief Business Officer, will oversee the Investor Relations function on an interim basis.

You May Also Be Interested In

• Rapid Line sees stock surge with no known corporate cause
• FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
• Aurinia settles patent dispute with Teva over generic voclosporin